ALK and lung carcinoma: To sum up, in lung cancer the current National Comprehensive Cancer Network (NCCN), Domestic Lung Cancer Clinical Guidelines, and National Health and Family Planning Commission Diagnosis and Treatment Norms suggest that some driver gene variants, including the mutation of EGFR, KRAS, BRAF; the mutation or amplification of HER2 (human epidermal growth factor receptor 2), ALK, ROS1, and RET rearrangements; and the MET copy number amplification or variable shear variations in MET exon 14 are the essential parts of the “core gene list” [20].